[Clinical study on relationship between sluggishness of lung-defensive qi and levels of vasoactive intestinal polypeptide and thromboxane B2].
OBJECTIVE
To explore the nature of pathology of sluggishness of lung-defensive qi and to offer objective experimental indexes for weifen syndrome (defensive phase syndrome).


METHODS
According to the completely random design, the plasma levels of vasoactive intestinal peptide (VIP) and thromboxane B2 (TX2) of 19 patients with weifen syndrome and 13 patients with qifen syndrome (qi phase syndrome) were detected by radioimmunoassay. The plasma levels of VIP and TX2 at different stages of weifen syndrome and qifen syndrome were observed.


RESULTS
The plasma levels of VIP in weifen syndrome and in the late stage of weifen syndrome increased greatly at different stages as compared to qifen syndrome and the blank group (P < 0.01), while the plasma level of TX2 of weifen syndrome was higher only at the late stage than the blank group and qifen syndrome (P < 0.01). As for the levels of VIP and TX2 in weifen syndrome with different internal organs infected, there was no significant difference (P > 0.05).


CONCLUSIONS
VIP may be an index reflecting the pathology of weifen syndrome, and it is one of the material foundations of sluggishness of lung-defensive qi, but it has nothing to do with the infected internal organs. The level of TX2 increases only after the fever of patients with weifen syndrome subsided, so it can not be the basis for diagnosis of the early stage of weifen syndrome. It doesn't increase in qifen syndrome either, the mechanism remains to be further studied.
Zhao
Guo-Rong
GR
Department of Clinical Basic Traditional Chinese Medicine, The First Affiliated Hospital, Hunan College of Traditional Chinese Medicine, Changsha, Hunan Province 410007, China.
Chen
Xi-Jun
XJ
He
You-Shun
YS
Ai
Bi-Chen
BC
Wang
Meng-Qing
MQ
Liu
Ke-Li
KL
Yang
Hang
H
D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000097:blood* / Q000473:pathology; D008297:Male; D011863:Radioimmunoassay; D013577:Syndrome; D013929:Thromboxane B2 / Q000097:blood*; D014660:Vasoactive Intestinal Peptide / Q000097:blood*
D014660:Vasoactive Intestinal Peptide; D013929:Thromboxane B2